Trial Profile
A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Chlormethine (Primary) ; Acitretin; Bexarotene; Bexarotene; Corticosteroids; Imiquimod; Romidepsin
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides
- Focus Therapeutic Use
- Acronyms PROVe
- Sponsors Actelion Pharmaceuticals; Helsinn Therapeutics
- 25 Apr 2021 Results assessing the tolerability of topical chlormethine gel in Mycosis Fungoides Cutaneous T-cell Lymphoma, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
- 18 Mar 2021 Results published in the Helsinn media release
- 18 Mar 2021 According to a Helsinn media release, Ellen J. Kim is the principal investigator of this study.